The findings are not easy to discern, showing a higher risk of depression and suicidal thoughts in individuals receiving GLP-1 agonists but a lower risk of suicide attempts and completed suicides (McIntyre et al., 2025; Strumila et al., 2024). The gene discussed is GLP1R; the disease is depressive symptom measurement.